MedPath

Tagged News

AI and Data Collaboration: Key to Advancing Cell Therapy in Biopharma Industry

AIDrug Discovery
  • Cellular Origins CEO Edwin Stone highlights the challenge of proprietary data silos hindering AI and machine learning implementation in biopharma despite their potential to advance patient care.
  • The biopharma industry faces a critical decision between competitive isolation and collaborative data sharing that could accelerate breakthroughs in cell therapy development.
  • AI and machine learning technologies are making significant impacts on drug discovery, particularly in virtual and software environments where they've found their initial applications.

Northstrive Biosciences Advances AI-Powered Drug Discovery for Obesity and Cardiac Diseases

AIDrug Discovery
  • Northstrive Biosciences has initiated Phase II of its collaboration with Yuva Biosciences to develop AI-powered therapies targeting mitochondrial health in obesity and cardiac diseases.
  • The partnership leverages MitoNova™, YuvaBio's proprietary AI platform, to screen large-scale libraries of small molecules and identify candidates that promote mitochondrial health.
  • The collaboration aims to compile synthetic compounds for muscle preservation and metabolic health, addressing the root cause of aging and related conditions at the cellular level.
  • Northstrive's lead asset EL-22 uses an engineered probiotic approach to preserve muscle mass during weight loss treatments, including GLP-1 receptor agonist therapies.

Dual-Modal Approach Combining OCT and Raman Spectroscopy Achieves 97% Accuracy in Skin Cancer Detection

AIOncology
  • A novel dual-modal approach combining optical coherence tomography (OCT) and Raman spectroscopy has demonstrated 96.9% accuracy in differentiating melanoma from benign lesions when paired with machine learning algorithms.
  • Early melanoma detection significantly impacts patient outcomes, with 5-year survival rates dropping from 99% in early-stage cases to just 35% when the cancer metastasizes to distant organs.
  • This non-invasive diagnostic technique could potentially reduce reliance on painful biopsies while providing clinicians with more objective and rapid diagnostic capabilities for skin cancer.

Real-World Evidence Oncology Market Projected to Reach $3.51 Billion by 2035 with 14.7% CAGR

Real World EvidenceOncologyAIPrecision Medicine
  • The real-world evidence oncology solutions market is projected to grow from $893 million in 2025 to $3.51 billion by 2035, representing a compound annual growth rate of 14.7%.
  • Market growth is driven by increasing demand for real-world evidence in drug development, rising focus on value-based healthcare, growing global cancer incidence, and advancements in data analytics and AI technologies.
  • North America is expected to hold the largest market share in 2025, while the Asia-Pacific region is projected to experience the fastest growth during the forecast period.
  • The datasets segment is expected to account for the largest market share, while pharmaceutical, biotechnology, and medical device companies represent the primary end-user segment.

AI-Discovered Drug Rentosertib Shows Promising Phase IIa Results for Idiopathic Pulmonary Fibrosis

AIDrug Discovery
  • Insilico Medicine's Rentosertib, the first drug with both target and compound identified through generative AI, demonstrated significant lung function improvement in Phase IIa trials for idiopathic pulmonary fibrosis patients.
  • Patients receiving 60 mg daily of Rentosertib showed a mean improvement of +98.4 mL in forced vital capacity compared to a -20.3 mL decline in the placebo group over 12 weeks.
  • The drug exhibited a manageable safety profile across all dosage levels and showed dose-dependent anti-fibrotic and anti-inflammatory effects through biomarker analysis.
  • Results published in Nature Medicine represent the first clinical proof-of-concept validation of AI-driven drug discovery, with the company now engaging regulatory authorities for larger pivotal trials.

Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)

NCT05938920Active, Not RecruitingPhase 2
InSilico Medicine Hong Kong Limited
Posted 6/19/2023

Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis

NCT05975983RecruitingPhase 2
InSilico Medicine Hong Kong Limited
Posted 2/8/2024

Biotech Leadership Shuffle Continues as Industry Navigates Transformation in Q2 2025

AIOncology
  • Novo Nordisk undergoes significant executive restructuring following the departure of EVP Camilla Sylvest, with rare disease leader Ludovic Helfgott taking over expanded commercial strategy responsibilities.
  • Galapagos faces major leadership transition as CEO Paul Stoffels announces retirement plans while CFO Thad Huston departs, amid the company's ongoing transformation into a cell therapy-focused biotech.
  • Multiple biotechs including Hansa Biopharma, Creyon Bio, and Sutro Biopharma appoint new CEOs as the industry continues strategic realignment efforts.
  • Emerging companies across oncology, rare diseases, and AI-driven drug development strengthen their leadership teams with experienced executives from major pharmaceutical companies.

CyPath® Lung Demonstrates Clinical Impact in Real-World Lung Cancer Detection Cases

AI
  • bioAffinity Technologies released clinical evidence showing CyPath® Lung's effectiveness in diagnosing early-stage lung cancer through real-world case studies authored by Dr. Gordon Downie.
  • The noninvasive sputum-based test successfully detected a second primary lung cancer in a high-risk patient with previous lung cancer history, facilitating timely treatment decisions.
  • Clinical studies demonstrate CyPath® Lung achieves 92% sensitivity, 87% specificity, and 88% accuracy in detecting lung cancer in high-risk patients with small nodules.
  • Economic analysis suggests potential healthcare cost savings of $2,773 per Medicare patient and $6,460 per private-payer patient when integrated into standard lung cancer screening protocols.

MR-LINAC Technology Advances Precision Radiation Therapy Across Multiple Cancer Types

Precision MedicineAIOncology
  • MR-LINAC technology enables adaptive radiation treatment planning with real-time imaging, allowing clinicians to customize radiation delivery based on daily changes in patient anatomy and tumor position.
  • The technology has shown promising early results in reducing toxicity rates in pancreatic and prostate cancers by precisely targeting tumors while sparing nearby sensitive organs.
  • Despite longer treatment sessions and potential claustrophobia issues, MR-LINAC offers significant advantages for treating cancers near sensitive organs, with ongoing research exploring novel MR contrast agents and biology-adaptive radiation approaches.

The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study

NCT04075305Recruiting
UMC Utrecht
Posted 2/1/2019

Diagnexia Partners with Artera to Launch AI-Powered Prostate Cancer Test in UK

AI
  • Diagnexia has formed an exclusive partnership with Artera to bring the ArteraAI Prostate Biopsy Assay to the UK market, marking the first multimodal AI risk stratification tool for localized prostate cancer patients.
  • The AI test combines patient clinical data with biopsy slide analysis to predict 10-year distant metastasis risk and therapy benefit, eliminating the need for additional invasive procedures or expensive molecular tests.
  • Artera has launched the DIRECT-AI registry to evaluate the real-world impact of the ArteraAI test on clinical decision-making and patient outcomes in localized prostate cancer treatment.
  • Clinical validation data shows the test can identify 34% of patients who may benefit from short-term hormone therapy and demonstrates superior prognostic performance compared to standard risk stratification models.

Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy

NCT00268476Active, Not RecruitingPhase 2
Medical Research Council
Posted 7/8/2005

CEPI Awards $5 Million to Nagasaki University for Revolutionary 'Nanoball' mRNA Vaccine Platform

AI
  • CEPI has awarded up to $5 million to Nagasaki University to develop a novel 'nanoball' mRNA vaccine platform that could overcome current storage and delivery limitations of traditional mRNA vaccines.
  • The technology encases mRNA in nano-sized, negatively-charged particles instead of lipid nanoparticles, potentially enabling room temperature storage and improved vaccine stability.
  • Initial research will focus on developing an AI-enabled vaccine against severe fever with thrombocytopenia syndrome virus (SFTSV), a deadly tick-borne pathogen threatening East Asia.
  • If successful, the platform could be rapidly adapted for future pandemic threats and support the 100 Days Mission to develop vaccines against emerging pathogens within three months.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.